Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.
Prior to commencement of active treatment, 48.4% of subjects experienced at least one AE. The body system organ classes with the highest incidences of events (> 10%) were the nervous system (17.5%; mainly headache, 14.5%), infections and infestations (15.9%, mainly nasopharyngitis and upper respiratory tract infection, 4.0%), gastrointestinal system (12.4%, mainly diarrhea 3.2%) and musco-skeletal and connective tissue disorders (12.0%, mainly back pain, 4.0%), 32.9% of subjects experienced mild AEs, 38.6% experienced moderate AEs and 36 (7.2%) patients experienced severe AEs. The intensity of AEs was similar across all treatment groups. None of the AEs were deemed to be definitely related to the study treatment.
Three of the submissions did not support the proposal highlighting the impact the change in scheduling would have on product currently on the market, industry, pharmacists and consumers. Two submissions noted that there has not been a history of concern with this combination of substances. One submission, referring to the NEJM article, believed that a lack of information about the study means that it cannot be relied upon as there is not a meaningful assessment of the results.
This is a great option for those who are looking to promote a steady and improved release of GH to get the benefits of increases in growth hormone and subsequently Insulin Like Growth Factor -1 (IGF-1) with almost no side effects. This therapy is effectively used for anti-aging purposes as well as those with inflammatory conditions, disease or those who have low IGF-1 levels.

But let’s say you’ve already implemented the IGF-1 boosting strategies of adequate calories, sufficient protein, weight training, plenty of sleep, smart supplementation, mineral intake and alcohol moderation. Should you take the next step, wander into an anti-aging clinic, find an online pharmacy, lurk in the depths of bodybuilding forums, and begin IGF-1 injections?

I was keen to try out CJC 1295 because my gym buddies had been using it for a while with fast and positive results. Though I was a bit nervous about injecting myself! To my surprise, it was easier than I expected. So I ordered online with Peptides Clinics and received a fast and efficient service. Everything came packaged in ice packs and with relevant info. Initially, I tried with the lowest dosage of CJC-1295 which was 10 mg for 10 weeks. It wasn’t look before I was seeing results. In fact, I noticed pretty quickly an increase in lean muscle, and couldn’t believe the amount of weight I lost! Brilliant! But, I have been advised to try out the CJC 1295 Ipamorelin combination, which I will do soon!
In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.
CJC-1295 10mg (Up to 10 Weeks): Started Wednesday 21 st September 2016 weight 122 kilo. Belly measurement 122cm Thursday 22nd September Weight @ 3pm 118.5 kilo Belly Measurement 117cm Morning and night 3 pumps Stacking with CJC1295 injectable. Lots of energy feel great aches and pains starting to subside.I will be doing a few more courses in the near future. THANKS Awesome products. Shane Ridley
AOD9604 is a peptide fragment (hGH Fragment 177-191) of the C-terminus of Human Growth Hormone to which a tyrosine is added at the N-terminal end.  Studies have suggested that AOD9604 is more effective than its predecessor AOD9401 in its ability to stimulate lipolytic (fat burning) and anti-lipogenic activity. Like Growth Hormone, AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (prevents the transformation of  fatty food materials into body fat) both in laboratory testing and in animals and humans.  Recent  clinical research studies have shown that  AOD9604 did show a reduction of body fat in the mid abdominal area in both obese, over-weight, and average built people.
PCR amplification was carried out on cDNA equivalent to 100 ng of starting mRNA using the following murine oligonucleotide primers (expected and observed PCR product size): β3-AR forward, 5′-TCTAGTTCCCAGCGGAGTTTTCATCG-3′; (234 bp) reverse, 5′-CGCGCACCTTCATAGCCATCAAACC-3′; β-actin forward, 5′-ATCCTGCGTCTGGACCTGGCTG-3′; (559 bp) reverse, 5′-CCTGCTTGCTGATCCACATCTGCTG-3′.
Results: After a single injection of CJC 1295, there were dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC 1295 was 5.8–8.1 d. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
The expression of β3-AR RNA was assessed by RT by using radiolabeled primers and Southern blot analysis. Labeled bands were identified and semiquantitated by phosphorimaging. RT-PCR analysis demonstrated that ob/ob mice express lower amounts ofβ 3-AR RNA in their white (Fig. 3A) and brown (Fig. 3B) adipose tissues, compared with lean C57BL/6J mice, in agreement with others (14). Figure 3A shows the effect of saline, AOD9604, and hGH on β3-AR RNA expression in epididymal adipose tissue from both lean and obese mice, respectively. The level of β3-AR expression increased significantly in response to AOD9604 and hGH only in the obese mice, correlating with the significant decrease in epididymal adipose tissue weights seen in these mice. The same correlation was observed in brown adipose tissue, where increased expression of β3-AR was accompanied by a decrease in brown adipose tissue mass in both lean and obese mice (Fig. 3B).
Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective – they wouldn't ban them for no reason, would they?
Thymosin beta 4 (Tβ4) is the predominant form of thymosin in our bodies. It has been found in high concentrations in wound tissue and certain blood cells involved in clotting, signifying its important role in the healing process. In fact, recent studies have revealed that the first gene to be upregulated after an injury is the Tβ4 gene. As the body begins the recovery process, Tβ4 aids in the creation of new vessels in the injured area, which carry blood, nutrients, and reparative substances to the site. Tβ4 also has anti-inflammatory properties, and works to decrease the amount of inflammatory substances, called cytokines. Inflammation plays a large role in many of the symptoms associated with a large number of conditions (i.e., Lyme disease, CFS, FM, autoimmune diseases, infections, etc.), making the potential impact of Tβ4 quite extensive.
Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.
Finally, the hexadecapeptide AOD9604 did not induce allergenic reactions when consumed over 24 weeks. Blood of patients was analyzed for the presence of anti-AOD9604 antibody formation at various times and at the end of the studies (latest time point after 24 weeks). In none of the performed studies, at no time, were anti-AOD9604 antibodies detected in serum collected from any subjects in any treatment group.
Various experiments have been conducted to test the effectiveness of CJC 1295-DAC in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection. Mean half-life was shown to be 5.8-8.1 days, also after multiple doses mean IGF-1 levels remained above baseline for up to 28 days. No serious adverse reactions were reported in any group.

The full activation of the hGH-receptor requires dimerization of two receptor molecules by one intact growth hormone molecule. The hGH has two different binding regions, site 1 and site 2, which bind in a sequential manner to two different regions of the receptor. Only if this trimer of one hGH molecule and two receptors is formed, does the subsequent signal transduction pathway become initiated [27, 28]. The hexadecapeptide AOD9604 consists only of amino acids 177-191 of hGH with an additional tyrosine residue at the N-terminus. The binding site 1 of the hGH, which is located in the fourth helix [27], is partially overlapping with the sequence of AOD9604. However, binding site 2 of hGH is completely missing in AOD9604. Therefore, it was hypothesized that AOD9604 is unable to induce dimerization and thereby activation of the receptor. This has been confirmed in previous in vitro experiments. Competition binding assays in cells transfected with the 125I-hGH receptor have shown that AOD9604 is incapable of competing with hGH for binding [20]. In a highly sensitive BaF3 cell proliferation test Heffernan et al (2001) also showed that AOD9604 did not induce cell-proliferation even in very high dosages [20].
The second long-term study (METAOD006) was a randomized, double-blind, placebo-controlled, multi-center, parallel group study conducted at 16 Australian hospitals and medical centres. In that study 534 were enrolled but of those 502 clinically obese subjects (BMI ≥ 30 kg/m2 and ≤ 45 kg/m2; Median BMI: 36.3 kg/m2, range: 30 to 45.2 kg/m2; 44% males and 56% females) were randomized to receive a daily dose of 0.25, 0.5 or 1mg AOD9604 or placebo for 24 weeks. Prior to this treatment period all subjects underwent a 4-week single-blind placebo run-in period. After cessation of the treatment a 4-week follow-up phase was performed.
Two submissions were received, both in relation to AOD-9604. One submission did not comment on the scheduling proposal, but wished to inform the committee that the substance is an ingredient in cosmetic products being sold overseas, has an International Nomenclature Cosmetic Ingredient (INCI) name of 27701 sh-Oligopeptide-74 and is published in the International Cosmetic Ingredient Dictionary and Handbook as well as the International Buyer's Guide.
“We are delighted with these results,” stated Metabolic Pharmaceuticals CEO, Chris Belyea. “The evidence from the trial is that over 12 weeks AOD9604 induces competitive weight loss with accompanying health benefits at a low dose and has superior tolerability. Our next major focus is a partnership with a major pharmaceutical company to assist in financing late stage longer term human clinical trials for worldwide marketing approval as a prescription treatment.”
Mod GRF 1-29 and CJC-1295 are still being researched. As such, they are not yet medically utilized or approved. Though some firm protocols for the use of these peptides have been developed, the dosage of the compound is not yet medically confirmed. In a study conducted by researchers on 21 to 61 year-old subjects, it was found that depending on the dose, the concentrations of the growth hormone increased to up to 10 times for at least 6 days. Also, the concentration of IGF-1 increased to up to 3 times for 9 to 11 days.
Peptide Clinics is an Australian owned and operated company, based in Sydney, that specialises in providing premium peptides online, coupled with expert medical guidance in their safe and effective use. Under the supervision of our experienced hormone doctors, Peptide Clinics Australia services thousands of clients throughout Australia with great success.